1. Medtech Insight
  2. >>Archive

SYMPLICITY Results Make Life Difficult For Renal Denervation Programs

The big slice of the device industry, from large-cap firms to venture capitalists, with some stake in the renal denervation opportunity are trying to understand the new reality now that Medtronic’s pivotal Symplicity renal denervation device trial missed its endpoint.

Medtronic PLC’s bombshell news, the disappointing clinical results for its Symplicity renal denervation product, left a smoking crater on the medtech landscape during the JP Morgan Healthcare Conference (JPM) in San Francisco, held earlier this month. Large-cap executives and venture capitalists who saw great promise in the new therapeutic approach (see Also see "Renal Denervation Sparks Device Market Gold Rush" - Medtech Insight, 25 May, 2012.) spent time trying to gauge the size and scope of the damage on the medtech industry and their own particular portfolios.

The SYMPLICITY HTN-3 trial followed two successful trials that demonstrated efficacy for the approach of ablating nerves within the renal...

More from Archive

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.